Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ADMA 
ADMA Biologics Inc (ADMA)
Top performer.
Today’s top pick
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: ADMA (5-star) is a STRONG-BUY. BUY since 28 days. Profits (19.43%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Analysis of Past Performance
Type Stock | Historic Profit 201.59% | Avg. Invested days 36 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.33B USD | Price to earnings Ratio 26.9 | 1Y Target Price 25.74 |
Price to earnings Ratio 26.9 | 1Y Target Price 25.74 | ||
Volume (30-day avg) 3676013 | Beta 0.53 | 52 Weeks Range 6.40 - 23.64 | Updated Date 04/24/2025 |
52 Weeks Range 6.40 - 23.64 | Updated Date 04/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.83 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 46.35% | Operating Margin (TTM) 32.6% |
Management Effectiveness
Return on Assets (TTM) 21.24% | Return on Equity (TTM) 81.64% |
Valuation
Trailing PE 26.9 | Forward PE 28.99 | Enterprise Value 5162956288 | Price to Sales(TTM) 12.49 |
Enterprise Value 5162956288 | Price to Sales(TTM) 12.49 | ||
Enterprise Value to Revenue 12.11 | Enterprise Value to EBITDA 34.96 | Shares Outstanding 238564000 | Shares Floating 232872303 |
Shares Outstanding 238564000 | Shares Floating 232872303 | ||
Percent Insiders 2.59 | Percent Institutions 88.09 |
Analyst Ratings
Rating 4.5 | Target Price 25.74 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ADMA Biologics Inc
Company Overview
History and Background
ADMA Biologics Inc. was founded in 2004. The company is a biopharmaceutical company dedicated to developing, manufacturing, and marketing specialty plasma-derived products for the treatment of immune deficiencies and infectious diseases.
Core Business Areas
- Plasma-Derived Biologics: ADMA develops and manufactures plasma-derived biologics, including intravenous immune globulin (IVIG) and hyperimmune globulins.
- Plasma Collection: ADMA operates its own network of FDA-approved plasma collection centers to ensure a reliable supply of plasma for its manufacturing processes.
Leadership and Structure
ADMA Biologics is led by Adam Grossman, President and CEO. The company has a board of directors overseeing its operations.
Top Products and Market Share
Key Offerings
- BIVIGAMu00ae: BIVIGAM is an intravenous immune globulin (IVIG) product indicated for the treatment of primary immunodeficiency diseases (PIDD). Competitors: Grifols, CSL Behring, Takeda.
- ASCENIVu2122: ASCENIV is an intravenous immune globulin (IVIG) product indicated for the treatment of primary immunodeficiency diseases (PIDD). Competitors: Grifols, CSL Behring, Takeda.
- NABI-HB: NABI-HB is a hepatitis B immune globulin (HBIG) product indicated for post-exposure prophylaxis following exposure to blood containing hepatitis B surface antigen (HBsAg). Competitors: Grifols, CSL Behring
Market Dynamics
Industry Overview
The plasma-derived therapeutics market is experiencing growth driven by increasing diagnosis rates of immune deficiencies and infectious diseases, as well as advancements in manufacturing technologies.
Positioning
ADMA Biologics focuses on niche segments within the IVIG market, particularly targeting specific patient populations with its specialized products. ADMA's network of collection centers provides supply chain control
Total Addressable Market (TAM)
The global IVIG market is estimated to be worth tens of billions of dollars annually. ADMA Biologics is positioned to capture a portion of this market through its focused product portfolio and plasma collection capabilities.
Upturn SWOT Analysis
Strengths
- Proprietary manufacturing process
- Vertically integrated plasma collection network
- Specialized product portfolio targeting niche markets
- FDA-approved products
Weaknesses
- Limited product pipeline
- Reliance on plasma supply
- Relatively small market share compared to larger competitors
- Debt levels
Opportunities
- Expanding plasma collection network
- Developing new plasma-derived products
- Geographic expansion
- Strategic partnerships
Threats
- Competition from larger players with broader product portfolios
- Fluctuations in plasma supply and pricing
- Regulatory changes
- Patent expirations
Competitors and Market Share
Key Competitors
- GRFS
- CSL
Competitive Landscape
ADMA is smaller as compared to competitors, but its vertically integrated plasma collection and focus on niche products provides some competitive advantages.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical revenue growth is driven by increased sales of BIVIGAM and ASCENIV.
Future Projections: Future growth is expected to be driven by continued sales growth of existing products, expansion of the plasma collection network, and potential new product launches. Analyst estimates would be included here.
Recent Initiatives: Recent initiatives include expansion of plasma collection centers and investment in R&D for new product development.
Summary
ADMA Biologics is a biopharmaceutical company focused on plasma-derived products. Their vertical integration gives them some supply chain control. Competition from major players and debt are key risks to watch. Future growth depends on successful product sales and expanding their plasma collection network. Although small, the company is in an expanding market.
Similar Companies
CSL
Carlisle Companies Incorporated
CSL
Carlisle Companies Incorporated
GRFS
Grifols SA ADR
GRFS
Grifols SA ADR
TAK
Takeda Pharmaceutical Co Ltd ADR
TAK
Takeda Pharmaceutical Co Ltd ADR
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ADMA Biologics Inc
Exchange NASDAQ | Headquaters Ramsey, NJ, United States | ||
IPO Launch date 2013-10-17 | Co-Founder, President, CEO & Director Mr. Adam S. Grossman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 685 | Website https://www.admabiologics.com |
Full time employees 685 | Website https://www.admabiologics.com | ||
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.